Final analysis of Covaxin efficacy out; vaccine 65.2% effective against Delta variant
The Hindu
The efficacy analysis demonstrates Covaxin to be 93.4 per cent effective against severe symptomatic COVID-19 cases
Bharat Biotech's has demonstrated 77.8 per cent effectiveness against symptomatic COVID-19 and65.2 per cent . The company on Saturday, July 3, 2021, said it concluded the final analysis of Covaxin efficacy from Phase 3 trials. Also read:More Related News

The draft policy for “Responsible Digital Use Among Students”, released on Monday by the Department of Health and Family Welfare, has recommended that parents set structured routines with clear screen-time rules and prioritise privacy, safety, and open conversation with children on digital well-being.












